Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine

T Bottiglieri, P Godfrey, T Flynn, M W P Carney, B K Toone, E H Reynolds

Abstract

Cerebrospinal fluid (CSF) S-adenosylmethionine (SAM) levels were significantly lower in severely depressed patients than in a neurological control group. The administration of SAM either intravenously or orally is associated with a significant rise of CSF SAM, indicating that it crosses the blood-brain barrier in humans. These observations provide a rational basis for the antidepressant effect of SAM, which has been confirmed in several countries. CSF SAM levels were low in a group of patients with Alzheimer's dementia suggesting a possible disturbance of methylation in such patients and the need for trials of SAM treatment.

S-adenosylmethionine (SAM) is the sole methyl donor in many important methylation reactions in the nervous system, involving neurotransmitters, amines and polyamines, membrane phospholipids, proteins and nucleoproteins.1 SAM is intimately linked to the folate cycle and vitamin B12 metabolism, which provides many of the methyl groups required for the SAM mediated methylation reactions, via the synthesis of methionine by the enzyme methionine synthetase.2

In Italy clinical trials on severely depressed patients have suggested that SAM has antidepressant properties3 and this has now been supported by studies in several countries.4-7 There is also evidence that severe folate deficiency may lead, amongst other complications, to depression.8-11 Both sets of observations suggest that methylation reactions are important in the regulation of mood and may be implicated in some affective disorders.2,10

During our placebo controlled investigations of SAM in depression6 we have included examinations of cerebrospinal fluid (CSF) SAM before and after treatment. For these studies SAM was administered by the intravenous route daily for 14 days. While examining CSF SAM in a control group of patients with neurological disorders we noted that the lowest values were seen in patients with dementia.12 Recently an oral formulation of SAM has become available,13 and this has enabled us to examine CSF SAM in a small group of demented patients before and after oral SAM treatment for several months.

Patients and methods

CSF SAM was examined in a) neurological control groups comprising 16 patients with clinically definite multiple sclerosis, three with motor neuron disease, seven with unexplained peripheral neuropathy, one with benign intracranial hypertension, one with narcolepsy and one with encaphalomyelitis; b) 35 patients with severe depression according to Feighner criteria, all of whom scored 20 or more points on the Hamilton Rating Scale; c) nine patients with Alzheimer's dementia according to the DSM-3-R classification. The age and sex of the patient groups are summarised in table 1.

Thirty of the depressed patients participated in a double blind study of treatment either with intravenous SAM 200 mgs daily or intravenous placebo daily for 14 days. Sixteen patients received SAM and 14 placebo. Cerebrospinal fluid SAM was re-examined at the end of the trial. In three patients from each group the CSF was taken two hours after the last injection, and in the remainder 24 hours after the last injection.

Four patients with Alzheimer's dementia were treated openly with oral SAM 1200 mgs daily (400 mgs three times a day). CSF SAM was re-examined after treatment periods which ranged from four to eight months. Intravenous (200 mgs) and oral (400 mgs enteric coated tablets) SAM was supplied by Bioresearch, Milan, Italy. CSF and plasma SAM were determined in perchloric acid extracts by a double isotope enzymatic assay.14 We do not know if there is a rostro-caudal gradient in the CSF for SAM but lumbar puncture was always undertaken after overnight fasting and rest and the SAM assay undertaken on the first 5 mls of fluid.

Results

We found no sex differences for CSF SAM. The CSF SAM levels in the different patient groups are shown in table 1. The highest values

Table 1 CSF SAM in neurological controls, depression and dementia

<table>
<thead>
<tr>
<th>N</th>
<th>Neuronal controls</th>
<th>Multiple sclerosis</th>
<th>Depression</th>
<th>Alzheimer's dementia</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>16</td>
<td>35</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>6/7</td>
<td>6/10</td>
<td>13/22</td>
<td>6/3</td>
</tr>
<tr>
<td>Age (years)</td>
<td>49-7 (16-4)</td>
<td>41 (9-7)</td>
<td>52 (16-6)</td>
<td>60 (5-5)</td>
</tr>
<tr>
<td>CSF SAM</td>
<td>64 (5.11-9)</td>
<td>78 (0.23-9)</td>
<td>56 (0.13-9)</td>
<td>36 (13-8)</td>
</tr>
</tbody>
</table>

Values indicate mean (SD). Comparison with neurological controls using the t test:

*p = 2.10, t = 0.041
fr = 4.76, p = 0.0001
were seen in patients with multiple sclerosis. Although for this control subgroup the increase in CSF SAM compared with the remaining control subgroup was not statistically significant, we have documented the two control subgroups separately. Statistically significant lowering of CSF SAM was found in the groups with depression and with Alzheimer’s dementia compared with the neurological control group and with the two individual subgroups; the lowest levels occurring in the Alzheimer’s group (table 1).

The administration of intravenous SAM 200 mgs daily for two weeks to depressed patients is associated with a significant rise in CSF SAM, a phenomenon which is not seen after two weeks treatment with placebo (table 2). Higher values for CSF SAM are seen two hours after the last injection (67% increase) than 24 hours after the last injection (19% increase) (table 2). Oral SAM treatment (1200 mgs daily) for four to eight months was associated with a significant increase (62-5%) in CSF SAM in patients with Alzheimer’s dementia (table 3). The post-treatment values were within the neurological control range (tables 1 and 3).

Discussion

S-adenosylmethionine is a ubiquitous metabolite which, when administered intravenously in normal subjects and patients in single doses varying from 100 to 500 mgs, is rapidly eliminated from the circulation with a half-life of about 90 minutes.8 We have previously shown that following single oral doses of 400 to 1000 mgs in normal subjects peak plasma levels are achieved between two and six hours and SAM is thereafter rapidly metabolised from the circulation.16

In this study we have shown that following intravenous or oral administration SAM crosses the blood-brain barrier leading to a rise in CSF SAM (tables 2 and 3). In the placebo controlled study in depressed patients CSF SAM was re-examined either two or 24 hours after the last of 14 daily injections. In keeping with the pharmacokinetics of SAM in blood the greatest rise (67%) in CSF was seen at two hours, but even at 24 hours there was a 19% elevation. No rise was seen with placebo at two or 24 hours. After oral administration of SAM continuously for four to eight months in demented patients CSF SAM rose by nearly two-thirds from baseline levels into the control range.

The therapeutic potential of SAM in some forms of depression, especially endogenous depression, has now been reported in several countries.8,17 Until recently the trials have utilised parenteral SAM, but longer term oral SAM studies are now showing promising results.13,18,19 SAM is remarkably free from side effects, the main problem being the precipitation of hypomania or mania in some patients with bipolar depression (which can occur with any antidepressant), and is further evidence of its efficacy.18

We have demonstrated in a large series of severely depressed patients that CSF SAM is significantly lower than in two neurological control groups (table 1). Although in the subgroups of multiple sclerotic patients the CSF SAM is not significantly higher than the other neurological control patients the trend is such that we thought it appropriate to keep the subgroups separate, especially as some patients have been described recently with multiple sclerosis associated with abnormalities of vitamin B12 metabolism.19 The low level of CSF SAM in some patients with depression suggests that there may be an underlying disturbance in methylation within the nervous system and provides a rational basis for the therapeutic use of SAM, at least in this subgroup. We have recently confirmed further evidence of abnormal methylation in depression in the form of reduced erythrocyte methionine adenosyltransferase (MAT) activity,20 as was earlier reported by Alarcon et al.21 MAT is the enzyme responsible for the synthesis of SAM from SAMC precursor, an increase in the SAM/C decommission ratio leads to hypomethylation and a disturbed DNA methylation process.22

During our study of other neurological diagnostic groups it became apparent that patients with Alzheimer’s dementia had remarkably low levels of CSF SAM, significantly lower than in depression (table 1). This suggests that disturbance in methylation in the brain may also be important in some forms of dementia. The administration of oral SAM to four of our patients was associated with an increase in CSF SAM to within the control range (table 3) and was accompanied by an improvement in mood and cognitive measures such as to justify further controlled trials in this clinical situation.23 The potential importance of such studies has recently been indicated by Holliday24,25 who has reviewed the role of DNA methylation in “epigenetic” mechanisms which influence the long term functioning of tissues. He summarises evidence to support the view that the gradual loss of methyl groups derived from SAM could contribute to ageing.

Bottiglieri, Godfrey, Flynn, Carney, Toone, Reynolds


22 Holliday R. A different kind of inheritance: the methylation of DNA may be a major epigenetic mechanism by which gene-activity patterns—as opposed to genes per se—are passed from one generation of cells to another during development. Scientific American 1989;260(6):40-8.
Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine.

T Bottiglieri, P Godfrey, T Flynn, M W Carney, B K Toone and E H Reynolds

*J Neurol Neurosurg Psychiatry* 1990 53: 1096-1098
doi: 10.1136/jnnp.53.12.1096

Updated information and services can be found at:
http://jnnp.bmj.com/content/53/12/1096

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/